CPT code 55868 represents a laparoscopic retropubic radical prostatectomy that employs nerve‑sparing techniques and may use robotic assistance, with limited pelvic lymph node sampling for staging. This procedure is a cornerstone surgical option for clinically localized prostate cancer and is nationally significant due to its implications for cancer control, functional outcomes (continence and erectile function), and perioperative resource use. The code signals both the primary extirpative operation and limited lymph node evaluation, which affects operative planning and coding specificity.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, payer coverage themes, and typical sites of service. The publication outlines common billing considerations and related procedural grouping, benchmarks for utilization and site‑of‑service patterns, and recent policy developments that influence authorization and payment for minimally invasive prostatectomy approaches. The summary also highlights areas where coding detail matters for claims processing, including documentation of nerve‑sparing intent and lymph node sampling.

This national overview is designed for revenue cycle leaders, surgical practices, and health policy analysts seeking clear, actionable understanding of CPT code 55868 in clinical and payer contexts.